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Background: Statin therapy has shown to deplete atherosclerotic plaque lipid content and induce plaque regression.
However, how early the plaque lipid depletion can occur with low-density lipoprotein cholesterol (LDL-C) lowering in
humans in vivo has not been fully described.
Methods: We enrolled 43 lipid treatment naïve subjects with asymptomatic carotid atherosclerosis and LDL-C≥ 100
and≤ 250 mg/dl. Rosuvastatin 5–20 mg/day was used to lower LDL-C levels to < 80 mg/dl. Lipid profile and carotid
MRI scans were obtained at baseline, 3, 12, and 24 months. Carotid plaque lipid-rich necrotic core (LRNC) and plaque
burden were measured and compared between baseline and during treatment.
Results: Among the 32 subjects who completed the study, at 3 months, an average dose of rosuvastatin of 11 mg/day
lowered LDL-C levels by 47% (125.2 ± 24.4 mg/dl vs. 66.7 ± 17.3 mg/dl, p < 0.001). There were no statistically significant
changes in total wall volume, percent wall volume or lumen volume. However, LRNC volume was significantly
decreased by 7.9 mm3, a reduction of 7.3% (111.5 ± 104.2 mm3 vs. 103.6 ± 95.8 mm3, p = 0.044). Similarly, % LRNC
was also significantly decreased from 18.9 ± 11.9% to 17.9 ± 11.5% (p = 0.02) at 3 months. Both LRNC volume
and % LRNC continued to decrease moderately at 12 and 24 months, although this trend was not significant.
Conclusions: Among a small number of lipid treatment naïve subjects, rosuvastatin therapy may induce a
rapid and lasting decrease in carotid plaque lipid content as assessed by MRI.
Trial registration: ClinicalTrials.Gov numbers NCT00885872
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Atherosclerosis alone is thought to be a relatively benign
disease and progresses with aging; however, it is frequently
complicated by acute thrombosis, usually triggered by the
rupture or erosion of an atherosclerotic plaque which is
determined by plaque morphologic characteristics, local
composition and inflammation [1,2]. Plaque rupture or
erosion can lead to major cardiovascular events such as
acute coronary syndromes and strokes. The cardiovascular* Correspondence: cjr.malin@vip.163.com; yeping301@sina.com
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unless otherwise stated.events reduction with statin therapy demonstrated in
the past 2 decades is most likely induced by improved
plaque stability that is determined by lipid core size, fi-
brous cap thickness and the level of inflammatory infil-
trates and activity.
Development of high-resolution magnetic resonance im-
aging (MRI) techniques in recent years has made it possible
to directly assess plaque composition. Numerous studies
have shown that MRI creates high contrast for internal fea-
tures of plaques and that the combined information from
multiple contrast weightings is critical for distinguishing all
plaque components [3]. The accuracy and reproducibility
of carotid MRI has been extensively validated, using histo-
logical analysis of lesions [4,5]. Thus, carotid MRI can ac-
curately assess plaque tissue contents.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lipoprotein cholesterol (LDL-C) lowering with statin in-
duced plaque regression [6,7] and plaque lipid content
reduction [8,9]. However, how early the plaque lipid deple-
tion can occur with intensive LDL-C lowering in humans
in vivo has not been fully described.
Thus, we designed and conducted a prospective study,
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients,
(REACH study, NCT00885872), to test the hypothesis




Subjects were recruited and enrolled to the REACH
study if they met the following inclusion criteria: 1) age
18 to 75 years; 2) carotid stenosis 16 - 69% by ultra-
sound; 3) the maximum wall thickness ≥ 3 mm, an intact
fibrous cap as assessed by MRI; 4) LDL-C ≥ 100 mg/dl
and ≤ 250 mg/dl; 5) triglycerides ≤ 353 mg/dl; and 6) no
history of statin or other lipid treatment. 7) The patients
who were willing to be enrolled have to remain on the low
cholesterol dietary before the screening. Exclusion criteria
were: 1) uncontrolled hypertension; 2) severe heart dis-
ease; 3) peripheral arterial disease; 4) liver disease; 5) renal
dysfunction; 6) hypothyroidism; 7) uncontrolled hypergly-
cemia with an HbA1c > 9%; 8) familial hypercholesterol-
emia; 9) history of any lipid-lowering agents.
As shown in Figure 1, among 1108 subjects screened by


















Figure 1 REACH study recruitment, enrollment and completion.and suitable for carotid MRI scans. 46 subjects were con-
firmed to meet the above MRI requirements. Of the 46
subjects, 43 qualified for lipids and without any liver and
renal abnormalities and enrolled in the REACH study. Dur-
ing the study, 1 patient was withdrawn for protocol viola-
tions, 2 withdrew consent, 2 experienced adverse events
(one for increases in alanine aminotransferase and aspartate
aminotransferase, the other for increases in creatine kinase),
and 6 were excluded from the final analyses for poor image
quality or missing one or more scans. Thus, 32 subjects
completed the study with matched serial MRI scans and ac-
ceptable image quality.
The REACH study was carried out at the People Liber-
ation Army (PLA) General Hospital (Beijing, China) be-
tween March 29th, 2009 (first patient enrolled) and
February 26th, 2012 (last patient completing the study).
All procedures were performed according to the Declar-
ation of Helsinki, and the study protocol was approved
by the PLA General Hospital’s institutional review board.
All patients provided a written informed consent.
Statin therapy and follow-up
All subjects received an initial treatment of rosuvasta-
tin 10 mg daily. Dose adjustment was performed after
4 weeks according to the Chinese guidelines for the pre-
vention and treatment of adult dyslipidemia [10]. If LDL-C
levels were ≥ 80 mg/dl, or if HDL-C were < 40 mg/dl, rosu-
vastatin dose was increased to 20 mg. If LDL-C levels <
80 mg/dl, rosuvastatin dose was maintained at 10 mg.
Rosuvastatin dose was decreased to 5 mg when LDL-C
levels were < 50 mg/dl. The dose determined at 4 weeks
was maintained during the rest of the 24-month.
After the study initiation, regular clinic visits were
scheduled every 1 to 3 months over the 24-month follow-
up period. At each visit, vital signs, physical examination,
dietary counseling, adverse events monitoring and medi-
cation compliance calculation were performed. Serum
lipids, liver functions, kidney functions and muscle en-
zymes were assessed at 3, 12, and 24 months.
Magnetic resonance imaging protocol
High-resolution and multicontrast bilateral carotid MRI
scans were performed using a 3.0-T MRI scanner (Signa
Echo Speed, GE Healthcare, Waukesha, WI, USA) at base-
line, and at 3, 12, and 24 months. All follow-up MRI scans
were performed using the same imaging protocol and
carefully matched for scan coverage using the carotid bi-
furcation as an internal landmark. An index artery with
the worse maximum wall thickness was identified at the
baseline scan.
A standardized protocol was used to obtain 3-dimensional
time-of-flight (TOF), proton-density-weighted (PDW),
T2-weighted (T2W) and T1-weighted (T1W) images.
Twelve axial images, centered at the bifurcation of
Table 1 Patient baseline characteristics
Characteristics Patients (n = 32)*
Age, mean (SD), y 60.8 ± 9.1
Male 25 (78.1%)
Body mass index, mean (SD)† 24.5 ± 2.7
History of hypertension 25 (78.1%)
History of diabetes mellitus 10 (31.3%)
History of coronary heart disease 3 (9.4%)
History of cerebrovascular disease 10 (31.3%)




Hypoglycemic agents 10 (31.3%)
*Data are expressed as number (%) unless otherwise specified.
†Calculated as weight (in kilograms) divided by the squared height (in meters).
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thickness for a total longitudinal coverage of 24 mm
without gap. Gadolinium contrast material (Magnevist
at 0.1 mmol/kg) was then administrated intravenously
and the T1-weighted scan was repeated 5–7 minutes
after contrast administration. Total acquisition time
for all images was approximately 40 minutes.
MRI analysis of plaque morphology and composition
All images were analyzed by experienced reviewers at
IBMarker Company, Seattle, WA, USA. An experienced
reviewer matched the axial images from all 4 time points
according to the distance from the carotid bifurcation.
Then, two experienced reviewers, who were blinded to the
order of MR scans, evaluated and interpreted all images
with matched locations of the index artery by reaching a
consensus opinion. This image review process was blinded
to laboratory results and clinical course.
Using a custom-designed image analysis tool (CASCADE,
IBMarker Company, Seattle, WA, USA), the lumen and
outer wall boundaries were identified [4,11]. The total vessel
area and lumen area (LA) were quantified by placing con-
tours around the outer wall boundaries and the lumen
of the carotid artery, respectively. Wall area (WA) was
calculated by subtracting the lumen area from the total
vessel area. Wall, lumen volumes and total vessel volumes
were obtained by adding the areas across slices and multi-
plying by the slice thickness (2 mm). Percent wall volume
(PWV), which is similar to percent atheroma volume
described in the IVUS literature, was calculated as: (wall
volume/total vessel volume) × 100%.
Lipid-rich necrotic core (LRNC) was identified and
automatically quantified using previously published
histologically-validated MRI criteria [4,5,11]. Specifically,
LRNC was identified using multicontrast weightings plus
post-contrast T1W images. LRNC usually appears as isoin-
tense to hyperintense on the TOF and pre-contrast T1W
images, has variable signal intensity on PDW and T2W
images, and has no or slight contrast enhancement com-
pared with the surrounding tissue on post-contrast T1W
images. Total LRNC volume was measured by multiplying
the slice thickness by the sum of the LRNC areas. The pro-
portion of LRNC relative to the wall volume (% LRNC)
was calculated as: (LRNC volume/wall volume) × 100%.
Both LRNC volume and % LRNC were calculated using
images containing LRNC.
According to previous studies, the reproducibility of
measuring plaque burden (ICC ranging from 0.96-0.99)
and LRNC size (ICC ranging from 0.94-0.99) with auto-
matic analysis is good to excellent [4,8,12].
Endpoints
The primary endpoint was the carotid plaque lipid content
presented as LRNC volume and %LNRC as measured byMRI. The secondary endpoint was the plaque burden pre-
sented as PWV.
Statistical analysis
The sample size was estimated according to previous
similar study [8]. For the change in % LRNC at baseline,
a sample size of approximately 26 patients was required
for 90% power and a 2-sided level of 0.05 to detect an
expected change of 2.7%, assuming an SD range from
2.5% to 5.3%. If approximately 25% of patients discontin-
ued from the study, then 35 patients allocated to study
medication would result in 26 patients completing the
study, which would provide sufficient power to assess
the primary end points.
Descriptive statistics are presented as mean ± SD. Changes
over time in lipids were compared to baseline using the
Wilcoxon’s signed-rank test (non-normally distributed
variables) or the paired t-test (normally distributed).
Changes over time in plaque measurements were compared
to baseline using the paired t-test when data presented
normally distributed. Otherwise, data were logarith-
mically transformed to normalize their distributions.
Associations test of plaque lipid content changes were
assessed using the Spearman rank correlation coeffi-
cient. Analysis was carried out using SPSS 17.0 (SPSS




Baseline demographic characteristics for the 32 subjects who
completed the trial are summarized in Table 1. The mean
age was 61 years and body mass index was 24.5 kg/m2.
Seventy-eight percent of subjects were male, 78% had
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disease and 31% had history of cerebrovascular disease.Changes in lipid levels under rosuvastatin therapy
Rosuvastatin 5–20 mg/day was initiated at the study entry
and dosage adjustment was made at 4 weeks to achieve
LDL-C levels < 80 mg/dl. The mean dose was 11 mg/day
during the remaining of the study. Lipid levels during the
2 years of rosuvastatin therapy were presented in Table 2.
At 3 months, LDL-C levels were significantly reduced by
47% (125.2 ± 24.4 mg/dl vs. 66.7 ± 17.3 mg/dl, p < 0.001).
HDL-C levels were increased by 4% (49.2 ± 14.7 mg/dl vs.
51.2 ± 11.8 mg/dl, p = 0.084). Triglycerides were lowered by
27% (142.3 ± 67.1 mg/dl vs. 103.3 ± 41.6 mg/dl, p < 0.001).Effects of rosuvastatin on plaque lipid content
At 3 months, LRNC volume was significantly decreased
by 7.9 mm3, a reduction of 7.3% (111.5 ± 104.2 mm3 vs.
103.6 ± 95.8 mm3, p = 0.044). % LRNC was significantly
decreased from 18.9% ± 11.9% to 17.9% ± 11.5% (p = 0.02)
as shown in Table 3.
The time course of plaque LRNC reduction over 24 months
is illustrated in Figure 2 and described in Table 3. Follow-
ing the initial significant reduction at 3 months, LRNC
volume continued to decrease moderately at 12 and
24 months. However, there were no statistically significant
differences when LRNC at 12 months compared to that at
3 months, and at 24 months vs. at 12 months. The de-
crease in % LRNC displayed the same trend.
Among the 32 subjects who completed the study, 68.8%
showed any decrease in LRNC volume and 62.5% had any
decrease in % LRNC. Figure 3 shows a representative MRI
of plaque lipid core regression over 2 years. However,
there was no subject demonstrated a completed depletion
of plaque lipid content over the 24 months. There were
31.2% of subjects showed no change or increase in LRNC.
Furthermore, magnitude of LRNC decrease over 24months
was significantly correlated with the LRNC volume at base-
line (r =− 0.53, p= 0.002) as shown in Figure 4.
Effects of rosuvastatin on carotid plaque burden
As shown in Table 3, during the 2 years of rosuvastatin
therapy, PWV and the total wall volume slightly decreased,Table 2 Lipid levels during the 24-month therapy
Baseline 3
Total cholesterol (mg/dl) 200.8 ± 29.8 13
LDL-cholesterol (mg/dl) 125.2 ± 24.4 66
HDL-cholesterol (mg/dl) 49.2 ± 14.7 51
Triglycerides (mg/dl) 142.3 ± 67.1 10
Data are presented as mean ± SD. LDL = low-density lipoprotein; HDL = high-density
to baseline.and lumen volume slightly increased. However, none of
these changes reached statistical significance.
Nevertheless, the decrease in total wall volume was sta-
tistically correlated with reduction in LRNC at 3 (r = 0.42,
p = 0.039), 12 (r = 0.44, p = 0.027) and 24 months (r = 0.45,
p = 0.024). The decrease in PWV over 24 months was sta-
tistically associated with reduction in LRNC (r = 0.40,
p = 0.005).
Discussion
It is well documented that major determinants of plaque
rupture are cellular and lipid composition and associated
inflammation [1,2] while specific plaque features associated
with propensity for disruption include higher lipid [2,13,14]
and macrophage content [2,15-17]. These high-risk plaque
features have been pursued as therapeutic targets and
measurable marker for plaque stabilization [18,19].
In addition to animal studies showed statin therapy let to
plaque lipid depletion from the existing plaque [20,21], in a
case–control study of patients randomized to 3 months
of pravastatin treatment or placebo prior to carotid end-
arterectomy, Crisby et al. provided histological evidence of
plaque lipid content reduction with therapy [22]. The
present study demonstrated that carotid plaque lipid con-
tent (LRNC volume and % LRNC) measured by MRI de-
creased significantly at 3 months with moderate-dose
rosuvastatin (11 mg/day) lowering LDL-C levels by 47% in
a group of lipid treatment naïve subjects. Our study pro-
vides in-vivo verification of rapid plaque lipid depletion.
Furthermore, taken together with a recent published study
[23] showing that intensified statin therapy (atorvastatin
80 mg) was associated with rapid reduction in vascular in-
flammations determined by fluorodeoxyglucose-positron
emission tomography, these findings may indicate evi-
dence of an early on-set of plaque stabilization via a rapid
reduction in arterial inflammation and a rapid plaque lipid
depletion with statin therapy.
After a rapid and statistically significant plaque lipid
depletion seen at 3 months in our study, carotid plaque
lipid content continued to decrease moderately and no
subject achieved completed plaque lipid depletion over
24 months of therapy. However, Carotid Plaque Com-
position by MRI during Lipid-lowering (CPC) study [9]
showed a statistically significant reduction in plaque lipidMonths 12 Months 24 Months
5.8 ± 24.7* 135.1 ± 36.0* 139.8 ± 24.4*
.7 ± 17.3* 65.5 ± 17.0* 69.8 ± 16.6*
.2 ± 11.8 52.9 ± 14.2† 53.8 ± 14.8*
3.3 ± 41.6* 110.6 ± 50.4† 98.7 ± 48.2*
lipoprotein. *p < 0.001 when compared to baseline. †p < 0.05 when compared
Table 3 Changes in LRNC and carotid arterial wall burden
Baseline 3 Months 12 Months 24 Months
LRNC, mm3 111.5 ± 104.2 103.6 ± 95.8* 101.7 ± 93.4* 97.7 ± 91.5*
LRNC% 18.9% ± 11.9% 17.9% ± 11.5%* 17.5% ± 11.2%* 16.7% ± 11.3%*
Wall volume, mm3 533.3 ± 208.9 523.1 ± 196.3 521.0 ± 194.2 528.0 ± 198.9
Lumen volume, mm3 522.1 ± 246.7 514.0 ± 234.2 512.1 ± 245. 6 537.6 ± 265.0
PWV, % 51.0% ± 8.2% 50.8% ± 8.5% 50.9% ± 9.0% 50.3% ± 8.6%
Data are presented as mean ± SD. Changes over time in plaque measurements were compared to baseline using the paired t-test (LRNC, LRNC % and lumen
volume were logarithmically transformed to normalize their distributions). LRNC = lipid-rich necrotic core; % LRNC = proportion of LRNC relative to the wall area;
PWV = percent wall volume. *P < 0.05 when compared to baseline.
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11% lower frequency of subjects with measurable LRNC
over 3 years. There are several important differences be-
tween the present study and CPC: (1) Chinese treatment
naïve subjects vs. Caucasian subjects with lipid treat his-
tory < 1 year; (2) lower LDL-C (125 mg/dl vs. 163 mg/dl)
and triglycerides (142 mg/dl vs. 202 mg/dl) levels at base-
line in our study subjects; (3) higher LRNC volume
(111.5 mm3 vs. 60.4 mm3) and % LRNC (18.9% vs. 14.2%)
in present study; (4) statin alone therapy vs. 2/3 of subjects
treated with combination lipid therapy. Saam et al. re-
ported significant differences in LRNC area between Chinese
and American patients with symptomatic carotid dis-
eases [24]. A large LRNC at baseline and treatment
naïve status in our study subjects may play a partial role in
the significant rapid plaque lipid depletion. However, the
lower dose of rosuvastatin used in current study might be
related to the moderated lipid depletion. Further stud-
ies are needed to examine the plaque response to therapy



















Figure 2 Reduction in LRNC and % LRNC during the 24 months of ro
24 months suggested that LRNC (red rhombuses) significantly decreased b
moderately at 12 and 24 months. †p < 0.05 when compared to baseline
12 months compared to that at 3 months, and at 24 months vs. at 12
same trend. *p < 0.05 when compared to baseline. Bars around the estiabnormalities and different magnitude of plaque lipid de-
pletion associated with intensity of LDL-C lowering.
The application of MRI in prospective serial studies of
human atherosclerosis has become more widespread be-
cause it is noninvasive, not involve ionizing radiation, su-
perior to other imaging modalities in discriminating tissue
contrast, and highly reproducible [25,26]. Prospective MRI
studies of carotid lesions [27-29] offer compelling evidence
that high-risk plaque features including a large LRNC,
strongly associate with clinical cerebrovascular events in
patients with asymptomatic 50%-79% carotid stenosis. The
high-risk plaque features are also seen in less severe sten-
osis. In an MR angiography study of carotid arteries with
0% stenosis, LRNC was present in 67.4% of nonocclusive
lesions [30]. Importantly, our study showed that plaques
with a larger LRNC are more likely to deplete (r = − 0.53,
p = 0.002) in response to a moderate-dose of rosuvasta-
tin therapy. These data indicate that plaques with large
LRNC are associated with a significantly higher risk of
















suvastatin therapy. The time course of plaque LRNC reduction over
y 7.9 mm3, a reduction of 7.3% at 3 months, and continue to decrease
. There were no statistically significant differences when LRNC at
months. The decrease of % LRNC (green squares) displayed the
mates are standard error bars. LRNC = lipid-rich necrotic core.
Figure 3 Representative MRIs showing plaque lipid depletion in right common carotid artery over 2 years. The lumen in red, outer wall
boundary in blue and lipid content in yellow of the carotid artery were identified and outlined in post-contrast T1W images. LRNC demonstrate
isointense on pre-contrast T1W images and TOF, and was detected as non-enhanced areas (relative to surrounding tissues) on CET1W images
with the corresponding pre-contrast T1W images used as reference. Regression in LRNC at the same location was found between the baseline,
3 months, 12 months and 24 months MRI scans. MRI = magnetic resonance imaging; LRNC = lipid-rich necrotic core; TOF = time-of-flight;
T1W = T1-weighted; T2W = T2-weighted; PDW = proton-density-weighted; CET1W = contrast enhanced T1-weighted.
Du et al. BMC Cardiovascular Disorders 2014, 14:83 Page 6 of 8
http://www.biomedcentral.com/1471-2261/14/83therapy and suggest a potential mechanism of statin ther-
apy in plaque stabilization leading to a lower risk for fu-
ture ischemic events. On the other hand, despite a similar
LDL-C lowering during the study, 31.2% of subjects
showed plaque LRNC no change or increase. The clinical
































LRNC volume at baseline (mm3)
Figure 4 Associations between changes of LRNC volume at
24 months and LRNC volume at baseline. Spearman rank correlation
showed that magnitude of LRNC decrease over 24 months
was significantly correlated with the LRNC volume at baseline
(r = − 0.53, p = 0.002).other risk features with LDL-C lowering requires to be
established in larger prospective clinical trials.
Although PWV and total wall volume was decreased
and lumen volume was increased non-significantly over
two years, these results were consistent with that seen in
ORION [8]. Furthermore, the total wall volume reduc-
tion was significantly associated with plaque lipid con-
tent decrease as indicated in CPC [9]. Considering the
natural increase of carotid plaque, the results indicate
that rosuvastatin may halt the natural progression of ca-
rotid atherosclerotic plaques.
We recognize the limitations of the current study.
Firstly, there was no control group since it is not ethic-
ally acceptable to study subjects with established carotid
atherosclerosis without therapy. Although we performed
the MRI analysis by an independent review group blinded
to all clinical information, lab results and MRI scan time
points, it may reduce the power to detect differences in
relevant plaque endpoints. And we cannot exclude the
possibility that LRNC may turn into fibrosis in months as
a natural process. However, most previous investigations
indicated that plaque seemed prone to progress rather
than regress without lipid-lowering therapy [31,32], and
LRNC was usually regard as one of the important factors
leading to plaque increase. Secondly, as subjects were
screened to have large plaques in this study, we are unable
to discern whether or not the observed changes in LRNC
volume and % LRNC occur in population with carotid wall
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criteria and image quality requirement,a small number of
subjects were enrolled and completed the trial. The degree
to which lipid depletion documented by MRI will translate
into an improvement in clinical outcomes remains un-
known. Thus, larger randomized controlled trials are
needed to confirm and further elucidate the effect of rosu-
vastatin on lipid-core reduction in patients with carotid
atherosclerotic plaque in the future.
Conclusions
In summary, the present study demonstrated rapid plaque
lipid depletion with a moderate-dose rosuvastatin therapy
among treatment naïve subjects with asymptomatic ca-
rotid lipid-rich atherosclerotic plaques. These findings
may indicate an early on-set of plaque stabilization that
could be achieved within the first three months of statin
treatment.
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